Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
hope big things coming, not only for profits but most importantly pets and people relieve from sickness of cancers
Be Strong, Great Faith is in something not coming yet but destined to come
Fact No1: The company has made solid progress towards marketing its products isopet and later radiogel, it does have the innovative products which will be generating revenue;
Fact No2: Please do your DD and review RDGL website carefully, it has world class management board and medical consulting board. These people have great education background and managerial experience;
Fact No3: The innovative products isopet had showed effectiveness and minimum side effects in treating dogs and cats cancers, since radiotherapy is still broadly applied treatment option for human cancers, and supposedly there is no species treatment response to radiotherapy, isopet and later radiogel will be highly possible for treating solid tumors in human clinics;
Fact No4: It is true that overall outstanding shares will be doubled, possibly up to 1.4Billion. But how come a company like this only value as 5M. Normally a startup biopharma company only having clinical trials but no products for marketing can still be worthy of tens of or even hundreds of millions.The value of this RDGL was much undervalued, it worth should be at least 100M, therefore considering the oncoming dilution, its should be at least 10 folds of its current market value. This share price of this stock will be more than a dime soon.
YES, THAT IS THE FACT
This is so great, have a nice and peaceful day!
WHY I OWNED SHARES OF RDGL--FROM GEORGE SHARP
Very sincere, honest person with integrity!!!
I believe in good people and true soldier for fighting against fraud in penny stocks;
Why I Own Shares of Vivos, Inc. (RDGL)
Initially Posted: July 17, 2018 1:10 p.m. PDT
As most of my followers know, I have earned a reputation for calling out penny stock scams. In spite of many detractors, usually consisting of those parties participating in such schemes, my tactics have been successful in ending many programs designed to defraud the public, albeit not before some people get hurt. Corix Bioscience (CXBS) comes to mind. Often, my work has lead to the incarceration of the perpetrators of such schemes, including and especially attorneys.
The OTC Markets (not to be confused with OTC Markets Group) is and continues to be the wild west of the stock market. When people ask me which tickers I would endorse, my answer almost invariably is, "Stay away from penny stocks". This is because I truly believe that almost every single ticker trading on the pink sheets and OTCQB---I would agree that a select few are real companies--is a scam, subject to a pump and dump scheme of some sort.
Although I have bought certain OTC tickers in the past, it has almost always been with the intent to gain rights as a shareholder so that I can subpoena the business records of the company1. Before today, I have never bought into an OTC ticker as an investment.
So here I am, accepting several past challenges to write something positive for a change. That is not an endeavor I find easy to accomplish in the OTC market.
This afternoon, I started accumulating shares of Vivos, Inc., ticker symbol RDGL.
I came across this company purely by accident. On most trading days, I scan the list of most active tickers to see what might be the newest pump and dump scheme. Today's action in RDGL, which is certainly a mystery to me, considering that the company has not issued a press release since May 31, drew my attention to the company2. I fully expected to find some sort of promotion ongoing, but have not thus far. That does not mean that there isn't one, although I hope not.
I am not going to go into a complete analysis of the financial position of the company, except to say that it has no money and no revenues. This is not unusual in a drug company that is researching its first treatment. The company has debt of about $5 million, but it is probably not insurmountable, especially considering the progress they are reporting with their cancer treatments. Most of the debt is in convertible notes which could eventually lead to dilution, but I have a gut feeling about this one. I think that the company may be able to get into research partnerships as they accomplish additional successful treatments, and that could alleviate those debts. Nonetheless, I find it encouraging that management does not appear to me to be taking a salary or consulting fees or is engaging in any other form of siphoning funds from the company. To me, this means that management is in it for the end game and not to steal from the shareholders. Hopefully, I am correct.
As I said, I am encouraged by news of progress, but I am accepting it at face value, not something I generally do. The company's most recent press release announced that it had "successfully treated canine soft tissue sarcoma with its proprietary IsoPet™ (RadioGel™), a hydrogel liquid containing tiny yttrium-90 phosphate particles that may be administered directly into a tumor." This is seemingly enormous news and together with previous announcements of success, enticed me enough to dip a cautious toe in the water.
~ George
P.S. Any claims of short positions (and squeezes) that will precipitate buying of Vivos stock (or any other penny stock for that matter) is utter nonsense, as is any claim of market maker manipulation. Stocks go up when there are more buyers than sellers and go downs when there are more sellers than buyers. That's the stock market.
About Vivos Inc. (as reported by the Company)
Currently, the Company has developed an Yttrium-90 based brachytherapy device, for the treatment of tumors in animals and humans. Brachytherapy uses highly localized radiation to destroy cancerous tumors by placing a radioactive isotope directly inside the treatment area. The product delivers therapeutic radiation from within the tumor without the entrance skin dose and associated side effects of treatment that characterize external-beam radiation therapy. This feature allows safe delivery of higher doses needed for treating both non-resectable and radiation-resistant cancers.
IsoPetTM for treating animals uses the same technology as RadioGelTM for treating humans. The Food and Drug Administration advised using different product names in order to avoid confusion and cross-use.
IsoPetTM is a hydrogel liquid containing tiny yttrium-90 phosphate particles that may be administered directly into a tumor. This hydrogel is an yttrium-90 carrier at room temperature that gels within the tumor interstitial space after injection to keep the radiation source safely in place. The short-range beta radiation from yttrium-90 localizes the dose within the treatment area so that normal organs and tissues are not adversely affected.
IsoPetTM also has a short half-life – delivering more than 90% of its therapeutic radiation within 10 days. This compares favorably to other available treatment options requiring up to six weeks or more to deliver a full course of radiation therapy. Therapy can be safely administered as an out-patient procedure and the patient may return home without subsequent concern for radiation dose to the family.
The IsoPetTM Solutions division of RDGL is using university veterinary hospitals to demonstrate the safety and therapeutic effectiveness for different animal cancers. The testing on feline sarcoma at the Washington State University is completed and the testing on canine soft tissue sarcomas at University of Missouri will begin in the near future.
The Company recently obtained clarification from the FDA Center for Veterinary Medicine that IsoPet is classified as a device for skin cancer therapy in cats and dogs. The FDA also reviewed and approved the product labeling. FDA does not require pre-market approval for veterinary devices so no additional approval is required for treating skin cancer, which is the largest market sector. RDGL is positioning itself so that after this demonstration phase, The Company can begin to generate revenues through the sale of IsoPetTM to University animal hospitals and private veterinary clinic consortiums.
The Company is also engaging the FDA for permission to use RadioGelTM for the treatment of advanced basal and squamous cell skin cancers in humans.
Disclaimer: As of the writing of this blog post, I own one million shares of Vivos, Inc. (RDGL). I reserve the right to buy or sell shares without further notice. I have not been compensated for this post in any way and the company was not aware that I was writing this blog post. I have reached out to the company to offer my services in their endeavor. This investment carries a very high risk and I am prepared to lose all of my money, provided that the company is acting in a truthful manner with the goal of benefiting the shareholders.
1 In the case of Corix Bioscience, I received shares as compensation for a judgment I held against the previous owner of the shares.
2 On July 17, 2018 at 10:10 a.m. PDT, I tweeted about my purchase in Vivos stock. An almost immediate spike in volume and share price occurred which may or may not have been a reaction to that tweet.
See the forest but not only the trees!!!
* It is true it had to convert or issue a huge amount of shares for getting out of the toxic debts, let say it will have 1.5B shares as OS;
* A company like this should be valued as much as hundreds of millions!!!
it has marketable cancer treatment products; Successful treatments on animals pave its way for human cancer treatment;
*So it should be valued at least 0.1 to 0.25 dollar soon.
Some rich investor or partner will swallow this in hanger!!!
Very reasonable expectation! It may become true soon!
this company is much undervalued! it will get back to at least 100 M.
Stunning result, it holds true!!!
I believe this holds true for RDGL. Know what you own, use the resources available to you, and treat this company as it should be treated. If you want some piece of shit ticker that will both P and D massively, then move on.
Yes, understanding it, that is why it has huge potential
Good News on the way
simply facts, Agreed no more
hopefully, this is it!
Animal Skin Cancer Treatment Classified as a Device by FDA
https://www.americanveterinarian.com/news/animal-skin-cancer-treatment-classified-as-a-device-by-fda
Fact!!!
Any news about great results from animals by isopet will prove the human trials of radiogel.
Remember:
*there was no differences of response among species to radiotherapy;
*minor invasive procedure of delivering isopet at outpatient and minimal collateral damages to normal tissue;
*Potentially huge to human patients who suffer from solid cancers.
Great results being presented on Friday
University of Missouri Veterinary Health Center oncologist Dr. Charles Maitz, will be presenting keynote talk about the successful results from our Canine testing with #IsoPet® on the state of art of the therapeutic usage of nuclear medicine @ACVR (American College of Veterinary Radiology)annual Conference on Friday Oct.19th in Texas.
https://twitter.com/radiogel?lang=en
Richland, WA, Sept. 26, 2018 (GLOBE NEWSWIRE) -- Vivos Inc (OTC PINK: RDGL) first therapy to canine treat soft tissue sarcoma is successful
Vivos Inc, a pharmaceutical company in the process of researching and developing minimally invasive treatments to combat cancer in humans and animals, is pleased to report several significant outcomes after its signature product, IsoPet®, was used to treat a hind-leg soft-tissue sarcoma in a Sheltie at the University of Missouri Veterinary Health Center in Columbia, Missouri.
Veterinary oncologist, Dr. Charles Maitz, reported that the treatment of the sarcoma resulted in a “complete response,” meaning tumor destruction and disappearance, together with a healthy recovery. Results will be presented in at the Veterinary Cancer Society’s annual conference in Louisville, Kentucky, October 17 – 20, 2018.
After therapy the pet owner commented that the dog had more energy than she can remember for a long time. “The owner is delighted!” said Dr. Maitz.
Study investigators were also pleased that IsoPet® met all RadioGel™ design performance criteria. Post-treatment imaging and dosimetry provided confirmatory data addressing the principal questions previously raised by an FDA review panel, including:
Near-uniform placement by injection and interstitial perfusion within the tumor without vascular clearance to normal organs and tissues
Very high therapeutic ratios (radiation dose to the tumor relative to normal organs)
Effective, highly localized, high-dose radiotherapy, and complete absence of adverse side-effects in critical normal tissues
The University of Missouri is now advertising availability of IsoPet® treatment for dogs and other species, including treatment of equine (horse) sarcoids.
Mike Korenko, Vivos Inc CEO stated “The successful treatment of the cat and dog subjects thus far increases the likelihood of IsoPet® becoming a practical solution in the treatment of animal cancer. Additionally, the data obtained at the University of Missouri will support the pre-clinical investigations required by the FDA to provide evidence that RadioGel™ can be safe and effective for treating various human cancers.”
About Vivos Inc. (OTC: RDGL)
Vivos, Inc. has developed an yttrium-90-based brachytherapy injectable device for treating tumors in animals (IsoPet®) and in humans (Radiogel™). Brachytherapy employs highly localized minimally invasive radiation to destroy cancerous tumors by placing a radioactive isotope directly inside the treatment area using the company’s proprietary hydrogel formulation. The injections deliver therapeutic radiation from within the tumor without the entrance skin dose and associated side effects of treatment that characterize external-beam radiation therapy. This feature allows safe delivery of higher doses needed for treating both non-resectable and radiation-resistant cancers.
IsoPet® for treating animals uses the same technology as RadioGelTM for treating humans. The Food and Drug Administration advised using different product names in order to avoid confusion and cross-use.
IsoPet® is a hydrogel liquid containing tiny yttrium-90 phosphate particles that may be administered directly into a tumor. This hydrogel is an yttrium-90 carrier at room temperature that gels within the tumor interstitial space after injection to keep the radiation source safely in place. The short-range beta radiation from yttrium-90 localizes the dose within the treatment area so that normal organs and tissues are not adversely affected.
IsoPet® also has a short half-life – delivering more than 90% of its therapeutic radiation within 10 days. This compares favorably to other available treatment options requiring up to six weeks or more to deliver a full course of radiation therapy. Therapy can be safely administered as an out-patient procedure and the patient may return home without subsequent concern for radiation dose to the family.
The IsoPet® Solutions division is using university veterinary hospitals to demonstrate the safety and therapeutic effectiveness for different animal cancers. The testing on feline sarcoma at the Washington State University is completed and the testing on canine soft tissue sarcomas at University of Missouri will continue.
The Company recently obtained confirmation from the FDA Center for Veterinary Medicine that IsoPet® is classified as a device for skin cancer therapy in cats and dogs. The FDA also reviewed and approved the product labeling. FDA does not require pre-market approval for veterinary devices so no additional approval is required for treating skin cancer, which is the largest market sector. Following this demonstration phase, Vivos can begin to generate revenues through the sale of IsoPet® to University animal hospitals and private veterinary clinic consortiums.
The Company is also engaging the FDA for clearance to market RadioGel™ for the treatment of advanced basal and squamous cell skin cancers in humans.
Safe Harbor Statement
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by the use of the words "may," "will," "should," "plans," "expects," "anticipates," "continue," "estimates," "projects," "intends," and similar expressions. Forward-looking statements involve risks and uncertainties that could cause results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, the Company's ability to successfully execute its expanded business strategy, including by entering into definitive agreements with suppliers, commercial partners and customers; general economic and business conditions, effects of continued geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, delays in completing various engineering and manufacturing programs, changes in customer order patterns, changes in product mix, continued success in technical advances and delivering technological innovations, shortages in components, production delays due to performance quality issues with outsourced components, regulatory requirements and the ability to meet them, government agency rules and changes, and various other factors beyond the Company's control.
CONTACT:
Vivos Inc.
Michael K. Korenko, President & CEO
MKorenko@RadioGel.com
Based on the Oct.10 PR,
"This sets the stage to pursue a substantial funding package to focus on expanding our animal testing and the pre-clinical testing required for the Investigational Device Exemption required by the FDA to initiate clinical trials for human skin cancer therapy and to more aggressively pursue development and commercial sales in the animal health sector with IsoPet™.” George will be negotiating for either a large funding or a partnership. Could be both. Go $RDGL !
who can figure out the number of outstanding shares?
I do not worry that but curious, even the share number will be doubled, considering the current market value of 5M, this was ridiculously undervalued. Something will happen to boost it!
Just wondering why 8K was out just before a big conference.
Great point!!!
Delivery of isopet or radiogel needs a minimum invasive procedure, which prevents the risks of cancer cells spreading out!
here is the meeting link
pay attention to the Saturday morning oral presentation schedule
http://vetcancersociety.org/conference/oral-abstract-schedule/
that is great!!!
A great sum of PRs associated with RDGL.
Patiently hold shares for true value at least dimes.
thank you for pointing this
GREAT
Expectations from Conference , a DD FROM YAHOO BOARD:
* On May 31, 2018. Vivos Inc stated "A veterinary cancer specialist at the University of Missouri—Columbia successfully treated a soft-tissue tumor in the hind thigh of a Sheltie". They are referring to Dr.Maitz. As part of the press report, they also mention ". The status of the dog patient will be followed over the next six months as we evaluate safety and efficacy of yttrium-90-RadioGel treatment". I am 100% sure they are presenting these results next week.
* As part of the report, they say "We anticipate treating another five or more canine subjects in the current test series. With this continuing series of treatments, we will further refine our product labeling and the training that will be provided to veterinarians that want to use our product in the future. We will also be sharing these data as we continue discussions with private veterinary clinic consortium's". Their MoU with Private Veterinary Hospital as Pilot Clinic for Commercial IsoPet® Therapy is inline with their promise in May to study the efficacy of treatment by recruiting more subjects.
* My favorite excerpt from their latest PR release "the company will introduce IsoPet® to the larger veterinarian community at the annual Veterinary Cancer Society Conference to be held in Louisville, KY October 17-20, 2018." IsoPet will be marketed for the first time to the pharma & scientific community backing its value using their research results from successfully treating their animal subjects.
* There will a major PR article next week during/immediately-after the conference.
* Several tweets/messages will be shared with the investors on the acceptance of IsoPet and RadioGel as treatment options for several cancer models.
* Every statement they release will have a credible, well-cited and peer-reviewed research component as a backbone.
RDGL$ will receive major coverage locally and globally starting from this week.
Expected GOOD NEWS SOON
Why a company like this eagerly wants to broadcast its presentation?
The results would be stunning!!!
Exactly 5 DAYS from today, Dr. Mike Korenko along with University of Missouri Veterinary Health Center oncologist Dr. Charles Maitz, will be taking center stage in Louisville, Kentucky to present successful results from our Canine testing with IsoPet®.
https://twitter.com/radiogel?lang=en
Radiation Oncology Market Worth $10.1 Billion By 2025
The global radiation oncology market size is expected to reach USD 10.1 billion by 2025, according to a new report by Grand View Research, Inc. It is projected to witness a CAGR of 6.5% over the forecast period. Rising prevalence of cancer is the primary factor responsible for substantial growth of the market for radiation oncology.
Technological advancements resulted in increased adoption of radiation oncology as primary cancer treatment. Development of compact advanced radiotherapy options such as CyberKnife, Gamma Knife, and tomotherapy are expected to complement this growth. These advanced methods pose lesser postoperative complications and faster recovery time.
Increasing per capita healthcare expenditure is also an important macroeconomic factor driving market growth. In addition, with the aid of supportive government initiatives and awareness, patients are not hesitant to opt for advanced treatment options. For instance, per capita health expenditure witnessed exponential growth of more than 55.0% from 1995 to 2014, as stated by the World Bank Group.
https://www.grandviewresearch.com/press-release/global-radiation-oncology-market
The Y90 Hydrogel become immobilized at body temperature after delivery, therefore the toxicities related to radioembolization become very limited. hope the presentation at oncoming meeting emphasizes above advantage, this will be huge enough.
A nice review paper about Y90 and related clinical info about its glass sphere delivery
https://www.ncbi.nlm.nih.gov/pubmed/28740906
Adv Radiat Oncol. 2016 Aug 18;1(4):351-364. doi: 10.1016/j.adro.2016.08.003. eCollection 2016 Oct-Dec.
The development, commercialization, and clinical context of yttrium-90 radiolabeled resin and glass microspheres.
Westcott MA1, Coldwell DM2, Liu DM3, Zikria JF4.
Author information
Abstract
Selective internal radiation therapy has emerged as a well-accepted therapeutic for primary and metastatic hepatic malignancies. This therapeutic modality requires the combined efforts of multiple medical disciplines to ensure the safe delivery of yttrium-90 (90Y)-labeled microspheres. The development of this therapy followed decades of clinical research involving tumor vascularity and microsphere development. Today, it is essential that treating physicians have a thorough understanding of hepatic tumor vascularity and 90Y microsphere characteristics before undertaking this complex intervention. This review explores the contributions of early investigators of this therapy, as well as the development, US Food and Drug Administration approval, manufacturing process, and attributes of the 2 commercially available 90Y radiolabeled microsphere device to clarify the key physical differences between the products.
BASIC characteristics of 90Y.
90Y is produced for labeling of microspheres by the neutron bombardment
of stable yttrium 89 but can also be developed by chemical separation from its parent isotope strontium 90.2 The decay of 90Y is primarily through b() emission of a high-speed electron to stable zirconium-90 with an
average energy of 0.9367 MeV, a mean tissue penetration
of 2.5 mm and a maximum of 11 mm, and a half-life of 2.67 days (64.2 hours).
Smart decision to go for human skin cancer trial first
successful treatment on aminals prove it and will be presented
technically proven delivery of high dose Y-90 and speared the normal tissue are the keys
GOT IN ANOTHER HALF MILLION SHARES
RDGL presentation schedule at VCS annual conference on OCT 18-20
Saturday morning sponsored keynote presentation and Dr. Korento presentation
RDGL will have drastically public exposure
http://vetcancersociety.org/conference/oral-abstract-schedule/
RDGL presentation schedule at VCS annual conference on OCT 18-20
Saturday morning sponsored keynote presentation and Dr. Korento presentation
RDGL will have drastically public exposure
http://vetcancersociety.org/conference/oral-abstract-schedule/
VCS annual conference Oct.18-20
RDGL sponsored morning keynote presentation and Dr.Korenko presentation
Oct. 20 Saturday Oral Abstract Schedule
8:00 - 9:00 AM Dr. Katherine Goldberg KEYNOTE PRESENTATION:
Moving upstream: Transformative oncology practice through
a palliative care lens
Sponsored by Vivos, Inc.
9:15 - 9:30 am Dr. Michael Korenko
Directed high-dose radionuclide therapy of soft-tissue sarcoma
http://vetcancersociety.org/conference/oral-abstract-schedule/